| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 1,201,940 | 1,138,990 | 1,050,580 | 1,168,070 | 1,101,710 |
| Sales Growth | +5.53% | +8.42% | -10.06% | +6.02% | +7.01% |
| Net Income | 40,410 | -64,090 | -37,150 | 65,230 | 12,480 |
| Net Income Growth | +163.05% | -72.52% | -156.95% | +422.68% | -84.97% |
Nuvasive Inc (NUVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NuVasive, Inc. is one of the leading global medical device companies in the global spine market, focused on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform includes NuVasive's proprietary NVM5 and NVJJB, and Intra-Operative Monitoring services & support, MaXcess. The spine surgery product line includes products for the thoracolumbar and the cervical spine. The biologic product line used to aid the spinal fusion process or bone healing process include Osteocel Plus and Osteocel Pro allograft, as well as other allograft offerings, FormaGraft and AttraX. It acquired Simplify Medical, Ellipse Technologies, Biotronic NeuroNetwork and SafePassage. NuVasive has included its business under NuVasive Specialized Orthopedics, NuVasive Clinical Services and the NuVasive Clinical Services.
Fiscal Year End Date: 12/31